June 2025

A deep-dive for pharma/biotech IP teams, R&D leads, and institutional investors on PBM market power, formulary mechanics, IP asset valuation, […]

Why Litigation Data Outperforms Every Other LOE Signal Patent expiration dates are public. Orange Book listings are public. FDA tentative

Track Any Drug Pipeline Through Patent Filings: The Pharma Analyst’s Intelligence Playbook Why Patent Filings Beat Every Other Intelligence Source

The pharmaceutical market in the United States functions as a regulated trade-off between the necessity of innovation and the demand

Why Patent Data Is the Most Underused BD Tool in CDMO Sales Most CDMOs sell on the same four claims:

Global Key Takeaways The FDA’s Orange Book is not a passive regulatory registry. It is the legal terrain on which

Executive Summary: The Economics of Loss of Exclusivity In the pharmaceutical sector, the transition from patent exclusivity to generic or

A single ClinicalTrials.gov entry can redirect millions in legal fees. When a specialty pharma company quietly posts a Phase II

The global generic pharmaceutical industry is undergoing a technical overhaul. In 2024, the contract manufacturing market for generics reached a